Medical Professionals

Oncology

Bristol Myers Squibb (BMS) is a leader in the field of oncology, with a comprehensive portfolio of both approved and investigational medicines.

Our focus lies in four key areas:

• Through our focus on tumour biology and translational research, we identify the right treatments for suitable patients at the right time.
• We are exploring new therapies that have the potential to change existing standards of care.
• We are exploring opportunities for patients who cannot currently be treated using checkpoint inhibitors.
• In IO-responsive tumours, we try to increase, deepen, and/or prolong the body's natural response to recognise and destroy cancer cells.

Immunology

Living with an immune-mediated disease is a debilitating reality for hundreds of millions of people around the world. While there has been progress with research and therapeutic options, patients may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their physical, emotional and social well-being, making simple tasks and daily life a challenge.

At Bristol Myers Squibb, we are pursuing pathbreaking science in Immunology to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neurology. Our goal is to restore some of what immune-mediated diseases have taken away, empowering patients and their loved ones to take back their lives.